Pediatric psoriasis: Evolving perspectives

Eichenfield, Lawrence F.; Paller, Amy S.; Tom, Wynnis L.; Sugarman, Jeffrey; Hebert, Adelaide A.; Friedlander, Sheila Fallon; Siegfried, Elaine C.; Silverberg, Nanette B.; Cordoro, Kelly M.

doi:10.1111/pde.13382

Cited by 79 publications

(66 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the availability of new drugs in children as well, there is still a scarce number of randomized controlled trials evaluating therapies of moderate-to-severe psoriasis in children and adolescents. Therefore standardized management guidelines are lacking (Eichenfield et al, 2018). Long-term analysis in childhood are available for open-label etanercept, ustekinumab versus placebo (Landells et al, 2015;Paller et al, 2016), and more recently for adalimumab as well (Thaci et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Adalimumab in severe plaque psoriasis of childhood: A multi‐center, retrospective real‐life study up to 52 weeks observation

Lernia

Bianchi

Guerriero

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

The objective of this study is to determine drug effectiveness and safety of the tumor necrosis factor‐alpha blocker monoclonal antibody adalimumab in a real‐life cohort of 54 children and/or adolescents with severe plaque psoriasis. Retrospective, multicenter analysis over a 52‐week period is discussed in this study. Efficacy was determined by the percentage of patients achieving Psoriasis Area Severity Index (PASI 75) and PASI 90 at weeks 16, 24, and 52 and the response in biologic‐naïve versus non‐naïve patients. Safety was assessed by the number of patients experiencing at least one adverse event. At week 16, 29.6% of patients achieved a 90% PASI score reduction (PASI 90), while 55.5% of patients achieved a 75% PASI score reduction (PASI 75). Effectiveness was sustained through week 24, since PASI 90 response increased to 55.5% and PASI 75 response increased to 74.0% of patients. The PASI response rates did not differ between biologic‐naïve and non‐naïve patients. The drug was well tolerated and no serious infections were observed. Adalimumab was effective and safe in this cohort of children with severe plaque psoriasis in a 52‐week observation. Effectiveness did not differ between biologic‐naïve and non‐naïve patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Adalimumab in severe plaque psoriasis of childhood: A multi‐center, retrospective real‐life study up to 52 weeks observation

Lernia

Bianchi

Guerriero

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…P soriasis develops during childhood in almost onethird of cases, with an almost linear increase in prevalence rates until 18 years of age (1)(2)(3)(4)(5). Nail psoriasis affects over 50% of the adult population with psoriasis, and is even more prevalent in patients with psoriatic arthritis (PsA) (6)(7)(8)(9)(10)(11).…”

mentioning

confidence: 99%

“…Approximately one-third of children with psoriasis experience more severe or recalcitrant disease (5,22). Early identification of children with an increased risk for a severe disease course is essential for adequate intervention and subsequent limitation of disease progression.…”

mentioning

confidence: 99%

Nail Involvement as a Predictor of Disease Severity in Paediatric Psoriasis: Follow-up Data from the Dutch ChildCAPTURE Registry

Bronckers

Bruins²,

Geel³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

Little is known about the relationship between nail psoriasis and psoriasis severity in children, and there has been no longitudinal assessment of psoriasis severity related to nail psoriasis. The aim of this study was to assess whether nail psoriasis could serve as a predictor for a more severe disease course. De-identified data were obtained from the Child-CAPTURE registry, a daily clinical practice cohort of children with psoriasis, from September 2008 to November 2015. Cross-sectional analyses were performed at baseline. Longitudinal data until 2-year follow-up were analysed by linear mixed models. Nail psoriasis was present in 19.0% of all 343 patients at baseline and cross-sectionally associated with higher Psoriasis Area and Severity Index (PASI) (p = 0.033). Longitudinal analysis demonstrated higher PASI (p < 0.001) during 2-year follow-up in patients with nail involvement at baseline. These findings suggest that nail psoriasis is a potential clinical predictor for more severe disease course over time in paediatric psoriasis.

show abstract

“…Studies on scalp psoriasis in children and potential associations with clinical characteristics are sparse. In children, the scalp is commonly reported as the initial site of presentation and scalp psoriasis tends to develop more frequently in girls than in boys . One multicentre study reported scalp psoriasis more frequently in severe vs. moderate psoriasis but the finding did not reach statistical significance .…”

Section: Comparison Of Clinical Characteristics Between Children Withmentioning

confidence: 99%

The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross‐sectional findings from the Dutch Child‐CAPTURE registry

et al. 2019

View full text Add to dashboard Cite

show abstract

Pediatric psoriasis: Evolving perspectives

Cited by 79 publications

References 89 publications

Adalimumab in severe plaque psoriasis of childhood: A multi‐center, retrospective real‐life study up to 52 weeks observation

Adalimumab in severe plaque psoriasis of childhood: A multi‐center, retrospective real‐life study up to 52 weeks observation

Nail Involvement as a Predictor of Disease Severity in Paediatric Psoriasis: Follow-up Data from the Dutch ChildCAPTURE Registry

The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross‐sectional findings from the Dutch Child‐CAPTURE registry

Contact Info

Product

Resources

About